Excessive erythrocytosis and the hypertensive phenotype at high altitude: emerging evidence and unresolved questions.

Systemic hypertension at high altitude is clinically important but mechanistically heterogeneous. Excessive erythrocytosis (EE), commonly discussed in relation to high-altitude polycythemia (HAPC) or the erythrocytotic component of chronic mountain sickness (CMS), is one of the most visible maladaptive responses to chronic high-altitude hypoxia. Emerging human studies suggest that erythrocytosis burden may be associated with the hypertensive phenotype at high altitude. Here, we critically evaluate the evidence linking EE and systemic hypertension and discuss the principal mechanistic pathways that may connect these phenotypes, including hyperviscosity-related vascular stress, endothelial dysfunction, hypoxemia with sleep-disordered breathing, sympathetic activation, and renal-metabolic disturbance. Current evidence can be organized into three tiers: direct association studies, indirect human physiological studies, and clinical extension studies addressing vascular or organ-damage phenotypes. The evidence base remains limited in sample size, predominantly cross-sectional, and largely restricted to selected high-altitude populations, especially Tibetans. Available data support association more strongly than causation. The key unresolved question is whether EE is a causal determinant of high-altitude hypertension, a marker of more severe hypoxic maladaptation, or a maladaptive amplifier within a broader blood pressure dysregulation phenotype. Clarifying this distinction will require phenotype-rich longitudinal studies integrating hemoglobin burden, blood viscosity, oxygenation, sleep-disordered breathing, ambulatory blood pressure, and vascular phenotyping.